Get the Stockscreener App
75.88
0.26%
0.20
After Hours:
75.88
Insmed Inc stock is traded at $75.88, with a volume of 935.94K.
It is up +0.26% in the last 24 hours and up +6.93% over the past month.
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
See More
Previous Close:
$75.68
Open:
$75.78
24h Volume:
935.94K
Relative Volume:
0.62
Market Cap:
$13.46B
Revenue:
$342.96M
Net Income/Loss:
$-864.29M
P/E Ratio:
-14.40
EPS:
-5.27
Net Cash Flow:
$-636.03M
1W Performance:
+4.42%
1M Performance:
+6.93%
6M Performance:
+244.91%
1Y Performance:
+216.96%
1-Day Range:
$74.79
$76.65
1-Week Range:
$70.94
$76.65
52-Week Range:
$21.92
$80.53
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
75.88 | 13.46B | 342.96M | -864.29M | -636.03M | -5.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed Insiders Sold US$3.8m Of Shares Suggesting Hesitancy - Simply Wall St
Charles Schwab Investment Management Inc. Purchases 137,670 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Qsemble Capital Management LP Purchases Shares of 23,155 Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Natixis Advisors LLC Makes New $1.53 Million Investment in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed (LTS:0JAV) 3-Year Revenue Growth Rate : 8.90% (As of Sep. 2024) - GuruFocus.com
Loomis Sayles & Co. L P Has $88.34 Million Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
251,739 Shares in Insmed Incorporated (NASDAQ:INSM) Purchased by Westfield Capital Management Co. LP - MarketBeat
Intech Investment Management LLC Buys New Shares in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Algert Global LLC Reduces Stock Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Invests $767,000 in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price - MarketBeat
Eagle Asset Management Inc. Sells 51,455 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Demystifying Insmed: Insights From 7 Analyst Reviews - Benzinga
Swiss National Bank Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Jennison Associates LLC Has $56.16 Million Stake in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed gains after ending $500M sales pact with Leerink - MSN
Insmed (NASDAQ:INSM) Shares Gap UpWhat's Next? - MarketBeat
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On TuesdayEnergizer Hldgs (NYSE:ENR) - Benzinga
Insmed ends sales agreement with Leerink Partners By Investing.com - Investing.com Canada
Insmed stock gains as $500M sales pact ends (INSM:NASDAQ) - Seeking Alpha
First Turn Management LLC Has $26.02 Million Stake in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Oppenheimer Asset Management Inc. Buys 7,751 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed's Options: A Look at What the Big Money is Thinking - Benzinga
Analysts Set Insmed Incorporated (NASDAQ:INSM) Price Target at $83.07 - MarketBeat
Victory Capital Management Inc. Has $33.29 Million Stake in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
WCM Investment Management LLC Purchases 54,806 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Notable Monday Option Activity: INSM, MARA, ALGM - Nasdaq
Insmed stock target reduced, keeps Outperform on Q3 report By Investing.com - Investing.com Canada
TimesSquare Capital Management LLC Invests $35.32 Million in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Principal Financial Group Inc. Acquires 214,130 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Benzinga
Fiera Capital Corp Sells 13,112 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Van ECK Associates Corp Invests $9.14 Million in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Citizentribune
Insmed Issues $4.6M in Stock Options to New Hires at $68.32 Share Price | INSM Stock News - StockTitan
Insmed To Present at November 2024 Investor Conferences - Marketscreener.com
Insmed (INSM) Set for Major Healthcare Conference Circuit: 4 Key Investor Events in November | INSM Stock News - StockTitan
17,682 Shares in Insmed Incorporated (NASDAQ:INSM) Acquired by Harbor Capital Advisors Inc. - MarketBeat
Insmed's SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Canada
Insmed's SWOT analysis: rare disease biotech stock poised for growth - Investing.com
New York State Common Retirement Fund Sells 29,520 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
INSMInsmed, Inc. Latest Stock News & Market Updates - StockTitan
Insmed (INSM) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Emerald Advisers LLC Buys 49,540 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates - MSN
Insmed (NASDAQ:INSM) Announces Earnings Results - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Q3 2024 Earnings Call Transcript - Insider Monkey
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates - MSN
Earnings call: Insmed reports strong Q3 growth, eyes brensocatib launch - Investing.com
Earnings call: Insmed reports strong Q3 growth, eyes brensocatib launch By Investing.com - Investing.com UK
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Michael Alexander | Chief Legal Officer |
Sep 13 '24 |
Sale |
74.35 |
27,871 |
2,072,223 |
67,856 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 13 '24 |
Option Exercise |
34.03 |
26,969 |
917,755 |
133,103 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 16 '24 |
Option Exercise |
34.03 |
13,436 |
457,227 |
119,570 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 12 '24 |
Option Exercise |
34.03 |
635 |
21,609 |
106,769 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 13 '24 |
Sale |
74.90 |
26,969 |
2,019,978 |
106,134 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 16 '24 |
Sale |
74.92 |
13,436 |
1,006,625 |
106,134 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 12 '24 |
Sale |
74.92 |
635 |
47,574 |
106,134 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):